Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 9/20 | 0.45 |
| ▸ | JAK2 | O60674 | 3/20 | 0.45 |
| ▸ | JAK1 | P23458 | 3/20 | 0.45 |
| ▸ | BTK | Q06187 | 4/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.37 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21537267 | 1.00 | JAK3 (0.45) | JAK3JAK2JAK1BTKTYK2 | |
| SCHEMBL24541727 | 1.00 | JAK3 (0.45) | JAK3JAK2JAK1BTKTYK2 | |
| SCHEMBL29470029 | 0.95 | JAK3 (0.42) | JAK3JAK2JAK1BTKTYK2 | |
| SCHEMBL20892891 | 0.90 | TEAD1 (0.45) | JAK3JAK2JAK1BTKFGFR1 | |
| SCHEMBL25229791 | 0.88 | TEAD1 (0.49) | JAK3JAK2JAK1BTKTEAD1 | |
| SCHEMBL17915688 | 0.87 | JAK3 (0.45) | JAK3JAK2JAK1BTKTYK2 | |
| SCHEMBL19240547 | 0.87 | JAK3 (0.45) | JAK3JAK2JAK1BTKTYK2 | |
| SCHEMBL18431347 | 0.87 | JAK3 (0.45) | JAK3JAK2JAK1BTKTYK2 | |
| SCHEMBL25365294 | 0.83 | JAK3 (0.38) | JAK3JAK1MEN1POLBMAPT | |
| SCHEMBL19240549 | 0.83 | JAK3 (0.41) | JAK3JAK2JAK1BTKTYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186574-B2 | Inhibitors of EGFR and/or HER2 and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20200199121-A1 | INHIBITORS OF EGFR AND/OR HER2 AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2020-06-25 | — | — | US | disclosed |
| US-10464949-B2 | Thiazolyl-containing compounds for treating proliferative diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190119301-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119301-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | BTK, BCL9L, BCL9 | JAK3 182/4885JAK2 8/4885JAK1 117/4885 |
| US-11186574-B2 | Inhibitors of EGFR and/or HER2 and methods of use | EGFR, ERBB2, ERBB3 | JAK3 594/4885JAK2 68/4885JAK1 423/4885 |
| US-10464949-B2 | Thiazolyl-containing compounds for treating proliferative diseases | BTK, BCL9L, BCL9 | JAK3 182/4885JAK2 8/4885JAK1 117/4885 |
| US-20200199121-A1 | INHIBITORS OF EGFR AND/OR HER2 AND METHODS OF USE | EGFR, ERBB2, ERBB3 | JAK3 594/4885JAK2 68/4885JAK1 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.